Financial Performance Highlights

  • H1 FY27 Consolidated Revenue: ₹411 crore
  • H1 FY27 EBITDA Margin: 18.82% (slightly higher than Q1 FY27's 17.6%)
  • H1 FY27 PAT Margin: 11.88% (significantly higher than Q1 FY27's 10.78%)
  • FY27 Revenue Guidance: ₹1,550 crore (conservative estimate, management expects to surpass by 10-15%)
  • FY27 PAT Guidance: ₹170-175 crore
  • Revenue Concentration: Approximately 50% of budgeted FY27 revenue achieved in first two quarters, with major revenue expected in remaining two quarters

Business Division Updates

Medical Technology (MedTech) Division:

  • Contributes 10-15% of current healthcare business (which represents 60% of total business)
  • Renalyx RXT 21 AI Dialysis Machine:
  • Production commenced at Bangalore facility
  • Clinical trials ongoing at specialized healthcare centers
  • 500+ confirmed export orders (UK, USA, Africa, Nepal, Bangladesh)
  • 350+ confirmed domestic orders
  • Execution timeframe: 6-9 months
  • CE certified and US approved
  • Cost of ownership 30-40% lower than imported machines over 5-7 years

IVD Business:

  • 700+ distributors, 200+ enterprise clients
  • Presence in 15 high-density states
  • 26 additional IVD medical devices manufacturing licenses received in Q2
  • Expanding to SAARC countries and US exports

Product Launch Roadmap:

  • December 2026: Commercial shipments of dialysis machines begin with export orders
  • January 2027: Sickle cell screening launch (subject to manufacturing license receipt); UK product sales begin
  • February 2027: UK operations start; AI-based medical device for physicians launch; CAR-T clinical trials begin
  • March 2027: US sales start (subject to US FDA approval); Caribbean export sales begin; Gut microbiome testing commercial rollout
  • March 2028: Third IVD manufacturing plant operational
  • June 2028: Advanced CAR-T treatment centers operational (subject to CDSCO approval)

Renewable Energy Division:

  • ₹3,000+ crore order pipeline backed by Maha PSU and government relationships
  • Orders spread over 3-5 year execution period
  • Approximately ₹300-400 crore executed in H1 FY27
  • Demerger planned by March 2027 (subject to NCLT approval, may spill to Q1 FY28)

Subsidiary Updates

  • US Subsidiary: Lord's Mark Industries Incorporation established; plans to set up dedicated laboratory and export full range of IVD/surgical products from India
  • UK Subsidiary: Secured all necessary MHRA approvals including for AI dialysis machine; sales to begin January 2027
  • Caribbean Operations: Plan to launch pathology laboratory chain with local partners from March 2027

Technology and Innovation

  • 30+ registered brands, 139 registered trademarks
  • Exclusive licenses from IIT Bombay, BARC, C-MET, BITS Pilani
  • Regulatory approvals: CDSCO, CE certification, MHRA UK, US FDA applied for
  • Flagship innovations:
  • Renalyx AI dialysis ecosystem with remote monitoring capabilities
  • AI-based radiation-free breast cancer screening device
  • Onco Diagnoscope for oral cancer diagnosis without biopsy
  • Sickle cell testing technology (15-minute results vs. 72 hours conventional)
  • Gut microbiome testing (CDSCO approval received)
  • CAR-T therapy addressing 18 cancer types (clinical trials begin February 2027)

Financial Disclosure Incident

  • Management acknowledged publishing two different versions of financial results signed by authorized signatories
  • Described as an "inadvertent error" by accounts team
  • Board has set up committee to monitor future publications and prevent recurrence
  • Letter submitted to exchange acknowledging error
  • Management expressed regret and embarrassment over the incident

Funding and Capital Structure

  • Promoter sold approximately 5% equity to maintain 75% minimum shareholding
  • ₹170 crore re-infused back into company by promoter
  • Company described as "adequately funded" for current requirements
  • Capex requirement for next financial year (FY28) for Asia's largest IVD/MedTech factory in Vapi or Lucknow

Market Strategy

  • Competitive Differentiation: Technology innovation, price advantage, indigenous manufacturing (85% parts in-house)
  • Go-to-market: Retail hospitals/clinics, government partnerships, export markets (UK, USA, GCC, SAARC)
  • Brand Ambassador: Rahul Dravid for IVD and pathology business

Manufacturing Capabilities

  • ISO certified devices
  • GMP compliant plants
  • Second plant operational, third plant commissioning soon

Q&A Session Highlights

  • Management addressed concerns about financial reporting reliability
  • Detailed technology exclusivity agreements with IIT Bombay and BARC
  • Explained competitive advantages in dialysis machines and diagnostic equipment
  • Discussed genome testing focus areas: preventive genomics, gut microbiome, pharmacogenomics
  • Addressed stock price performance constraints due to T2T segment status